PE20040691A1 - 4-piperazinilbencenosulfonilindoles afines con el receptor 5-ht6 - Google Patents
4-piperazinilbencenosulfonilindoles afines con el receptor 5-ht6Info
- Publication number
- PE20040691A1 PE20040691A1 PE2003001052A PE2003001052A PE20040691A1 PE 20040691 A1 PE20040691 A1 PE 20040691A1 PE 2003001052 A PE2003001052 A PE 2003001052A PE 2003001052 A PE2003001052 A PE 2003001052A PE 20040691 A1 PE20040691 A1 PE 20040691A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- compounds
- benzenosulfonil
- piperazin
- indol
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- -1 AMINO Chemical class 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41936902P | 2002-10-18 | 2002-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040691A1 true PE20040691A1 (es) | 2004-10-16 |
Family
ID=32108067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003001052A PE20040691A1 (es) | 2002-10-18 | 2003-10-15 | 4-piperazinilbencenosulfonilindoles afines con el receptor 5-ht6 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7022708B2 (https=) |
| EP (1) | EP1556037B1 (https=) |
| JP (1) | JP2006505559A (https=) |
| KR (1) | KR20050073560A (https=) |
| CN (1) | CN1309384C (https=) |
| AR (1) | AR041635A1 (https=) |
| AT (1) | ATE344030T1 (https=) |
| AU (1) | AU2003283265B2 (https=) |
| BR (1) | BR0315317A (https=) |
| CA (1) | CA2501172A1 (https=) |
| DE (1) | DE60309498T2 (https=) |
| ES (1) | ES2274285T3 (https=) |
| GT (1) | GT200300226A (https=) |
| MX (1) | MXPA05004128A (https=) |
| PA (1) | PA8586401A1 (https=) |
| PE (1) | PE20040691A1 (https=) |
| PL (1) | PL376479A1 (https=) |
| RU (1) | RU2324693C2 (https=) |
| TW (1) | TW200418456A (https=) |
| UY (1) | UY28026A1 (https=) |
| WO (1) | WO2004035047A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1401813B1 (en) * | 2001-06-07 | 2007-02-07 | F. Hoffman-la Roche AG | New indole derivatives with 5-ht6 receptor affinity |
| BRPI0308696B8 (pt) | 2002-03-27 | 2021-05-25 | Axovant Sciences Gmbh | composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos |
| PT1558582E (pt) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| MXPA06010543A (es) | 2004-03-15 | 2007-03-26 | Ptc Therapeutics Inc | Derivados de carbolina utiles en la inhibicion de la angiogenesis. |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
| EP1771169A1 (en) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| AR052308A1 (es) * | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
| JP2008507518A (ja) | 2004-07-22 | 2008-03-13 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎を治療するためのチエノピリジン |
| CN102114244A (zh) | 2004-09-30 | 2011-07-06 | 弗·哈夫曼-拉罗切有限公司 | 治疗认知障碍的组合物和方法 |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| EA013875B1 (ru) | 2005-08-12 | 2010-08-30 | Сувен Лайф Сайенсиз Лимитед | Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды |
| BRPI0614343A2 (pt) * | 2005-08-15 | 2011-03-22 | Wyeth Corp | derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6 |
| WO2007020654A1 (en) | 2005-08-16 | 2007-02-22 | Suven Life Sciences | An improved process for the preparation of losartan |
| WO2007084841A2 (en) * | 2006-01-13 | 2007-07-26 | Wyeth | Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors |
| ES2358549T3 (es) | 2006-11-09 | 2011-05-11 | F. Hoffmann-La Roche Ag | Arilsulfonil, pirrolidinas como inhibidores de 5-ht6. |
| JP5208963B2 (ja) | 2007-01-10 | 2013-06-12 | エフ．ホフマン−ラ ロシュ アーゲー | キマーゼ阻害剤としてのスルホンアミド誘導体 |
| CN101835748B (zh) * | 2007-10-26 | 2012-11-14 | 苏文生命科学有限公司 | 氨基芳基磺胺化合物及其作为5-ht6配体的用途 |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010032257A1 (en) * | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| US8575186B2 (en) | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
| AU2012207335A1 (en) | 2011-01-19 | 2013-07-25 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
| DK2838533T3 (da) | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
| US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
| CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN104557726B (zh) * | 2013-10-19 | 2019-05-24 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| WO2015090233A1 (en) | 2013-12-20 | 2015-06-25 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| EP3166924B1 (en) * | 2014-07-08 | 2019-02-20 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| JP7595413B2 (ja) | 2016-11-30 | 2024-12-06 | ケース ウエスタン リザーブ ユニバーシティ | １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 |
| WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN109232362B (zh) * | 2017-07-10 | 2022-12-27 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| CN120463721A (zh) | 2018-11-21 | 2025-08-12 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| FI4426434T3 (fi) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Pparg:n käänteisagonisteja ja niiden käyttöjä |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9116732D0 (en) | 1991-08-02 | 1991-09-18 | Fujisawa Pharmaceutical Co | Indole derivatives |
| FR2729144A1 (fr) | 1995-01-06 | 1996-07-12 | Smithkline Beecham Lab | Nouvelles diamines, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu' agents anti-arythmiques |
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| AU736256B2 (en) | 1997-07-11 | 2001-07-26 | Smithkline Beecham Plc | Novel compounds |
| GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
| WO2000058304A1 (en) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Heterocyclic sulfonamide derivatives |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| AU2001296193B2 (en) * | 2000-10-20 | 2006-04-27 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy |
| AU2002220715A1 (en) * | 2000-11-24 | 2002-06-03 | Smithkline Beecham Plc | Indolsulfonyl compounds useful in the treatment of cns disorders |
| CN1321110C (zh) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物 |
| PL374401A1 (en) * | 2002-06-05 | 2005-10-17 | F.Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
| JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物 |
| ES2311721T3 (es) * | 2002-09-17 | 2009-02-16 | F. Hoffmann-La Roche Ag | Indoles sustituidos en posicion 2,4 y su empleo como moduladores de 5-ht6. |
-
2003
- 2003-10-13 PL PL03376479A patent/PL376479A1/xx not_active Application Discontinuation
- 2003-10-13 CA CA002501172A patent/CA2501172A1/en not_active Abandoned
- 2003-10-13 EP EP03775181A patent/EP1556037B1/en not_active Expired - Lifetime
- 2003-10-13 DE DE60309498T patent/DE60309498T2/de not_active Expired - Lifetime
- 2003-10-13 RU RU2005115115/04A patent/RU2324693C2/ru not_active IP Right Cessation
- 2003-10-13 WO PCT/EP2003/011323 patent/WO2004035047A1/en not_active Ceased
- 2003-10-13 MX MXPA05004128A patent/MXPA05004128A/es active IP Right Grant
- 2003-10-13 KR KR1020057006683A patent/KR20050073560A/ko not_active Ceased
- 2003-10-13 JP JP2004544204A patent/JP2006505559A/ja active Pending
- 2003-10-13 CN CNB2003801014548A patent/CN1309384C/zh not_active Expired - Fee Related
- 2003-10-13 AT AT03775181T patent/ATE344030T1/de not_active IP Right Cessation
- 2003-10-13 ES ES03775181T patent/ES2274285T3/es not_active Expired - Lifetime
- 2003-10-13 AU AU2003283265A patent/AU2003283265B2/en not_active Ceased
- 2003-10-13 BR BR0315317-7A patent/BR0315317A/pt not_active IP Right Cessation
- 2003-10-14 TW TW092128412A patent/TW200418456A/zh unknown
- 2003-10-15 PA PA20038586401A patent/PA8586401A1/es unknown
- 2003-10-15 PE PE2003001052A patent/PE20040691A1/es not_active Application Discontinuation
- 2003-10-16 UY UY28026A patent/UY28026A1/es not_active Application Discontinuation
- 2003-10-16 US US10/687,091 patent/US7022708B2/en not_active Expired - Fee Related
- 2003-10-16 AR ARP030103764A patent/AR041635A1/es not_active Application Discontinuation
- 2003-10-17 GT GT200300226A patent/GT200300226A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT200300226A (es) | 2004-10-18 |
| PA8586401A1 (es) | 2005-08-04 |
| JP2006505559A (ja) | 2006-02-16 |
| US20040087593A1 (en) | 2004-05-06 |
| PL376479A1 (en) | 2005-12-27 |
| CN1309384C (zh) | 2007-04-11 |
| UY28026A1 (es) | 2004-04-30 |
| KR20050073560A (ko) | 2005-07-14 |
| WO2004035047A1 (en) | 2004-04-29 |
| AU2003283265A1 (en) | 2004-05-04 |
| MXPA05004128A (es) | 2005-06-22 |
| EP1556037A1 (en) | 2005-07-27 |
| DE60309498T2 (de) | 2007-08-30 |
| EP1556037B1 (en) | 2006-11-02 |
| ES2274285T3 (es) | 2007-05-16 |
| AU2003283265B2 (en) | 2009-03-05 |
| US7022708B2 (en) | 2006-04-04 |
| AR041635A1 (es) | 2005-05-26 |
| ATE344030T1 (de) | 2006-11-15 |
| TW200418456A (en) | 2004-10-01 |
| DE60309498D1 (de) | 2006-12-14 |
| CN1705480A (zh) | 2005-12-07 |
| RU2005115115A (ru) | 2006-01-20 |
| CA2501172A1 (en) | 2004-08-29 |
| RU2324693C2 (ru) | 2008-05-20 |
| BR0315317A (pt) | 2005-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040691A1 (es) | 4-piperazinilbencenosulfonilindoles afines con el receptor 5-ht6 | |
| EP0483881B1 (en) | 3-Amidoindolyl derivatives | |
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| PE20070751A1 (es) | Derivados de isoxazolidina como inhibidores de la interaccion de proteinas bcl | |
| US5703107A (en) | 3-aminoindolyl derivatives | |
| AR040500A1 (es) | Inhibidores de cinasas | |
| RS50621B2 (sr) | Inhibitori dipeptidil peptidaze | |
| DE60335869D1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| DE60229530D1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
| CY1106697T1 (el) | Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων | |
| JP2004521117A5 (https=) | ||
| PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
| ATE384058T1 (de) | Thiazolderivate | |
| AR035532A1 (es) | Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos | |
| PE20050193A1 (es) | Compuestos heterociclicos utiles como activadores de nurr-1 | |
| PE20021073A1 (es) | Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3 | |
| NO2012015I1 (no) | Dapoxetine i en hver form beskyttet av basis patent nr 330562 | |
| ECSP088457A (es) | Compuestos de benzamida útiles como inhibidores de la histona deacetilasa | |
| MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| PE20050141A1 (es) | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA | |
| PE20030718A1 (es) | Lactamas como antagonistas de taquiquininas | |
| EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |